Background. Integrins play a crucial role in the regulation process of cell proliferation, migration, differentiation, tumor invasion and metastasis. ITGA11, ITGB4 and ITGB8 are three encoding genes of integrins family. Accumulative evidences have proved that abnormal expression of ITGA11, ITGB4 and ITGB8 are a common phenomenon in different malignances. However, their expression patterns and prognostic roles for patients with non-small cell lung cancer (NSCLC) have not been completely illustrated. Methods. We investigated the expression patterns and prognostic values of ITGA11, ITGB4 and ITGB8 in patients with NSCLC through using a series of databases and various datasets, including ONCOMINE, GEPIA, HPA, TCGA and GEO datasets. Results. We found that the expression levels of ITGA11 and ITGB4 were significantly upregulated in both LUAD and LUSC, while ITGB8 was obviously upregulated in LUSC. Additionally, higher expression level of ITGB4 revealed a worse OS in LUAD. Conclusion. Our findings suggested that ITGA11 and ITGB4 might have the potential ability to act as diagnostic biomarkers for both LUAD and LUSC, while ITGB8 might serve as diagnostic biomarker for LUSC. Furthermore, ITGB4 could serve as a potential prognostic biomarker for LUAD. Subjects Bioinformatics, Genetics, Oncology, Translational Medicine Keywords ITGA11, ITGB4, ITGB8, Non-small cell lung cancer, Expression and prognostic analysis How to cite this article Wu P, Wang Y, Wu Y, Jia Z, Song Y, Liang N. 2019. Expression and prognostic analyses of ITGA11, ITGB4 and ITGB8 in human non-small cell lung cancer. PeerJ 7:e8299 http://doi.JP. 2017. miR19b-3p promotes the growth and metastasis of colorectal cancer via directly targeting ITGB8. XP. 2017. Integrin beta4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. Scientific Reports 7:40464 MS. 2016. Integrin alpha11beta1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer.
INTRODUCTION
Lung cancer is the most frequent malignancy and the leading cause of cancer-related death all over the world. Five-year survival rate for lung cancer patients ranges from 4% to 17% depending on disease stage and regional differences (Hirsch et al., 2017) . Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer and responsible for 85% to 90% of all lung cancer (Osmani et al., 2018) . Owing to the problems in early diagnosis, patients with NSCLC are often diagnosed at advanced stage, which contributes a lot to the dismal prognosis (Ellis & Vandermeer, 2011; Jan et al., 2019) . Thus, there is an urgent need to discover new diagnostic and prognostic biomarkers for NSCLC.
Integrins function as bridges between the extracellular matrix (ECM) and the cytoskeleton and work as radars to detect changes in the cellular microenvironment, which enables cells to react according the external milieu (Bianconi, Unseld & Prager, 2016; Ginsberg, 2014) . They play a crucial role in the regulation process of cell proliferation, migration, differentiation, tumor invasion and metastasis (Slack-Davis & Parsons, 2004) . Integrins family include 24 different transmembrane, multifunctional heterodimers and are composed of an α and a β subunit (Brakebusch et al., 2002) . There are 18 different α subunits and eight different β subunits in human body (Hynes, 1992) . Recently, the effects of integrins in tumor progression have been receiving a great deal of attention.
ITGA11 encodes integrin subunit α11, which dimerizes with β1 subunit and forms as a cell surface collagen receptor involved in the process of cell migration and collagen reorganization (Tiger et al., 2001) . Integrin α11 was overexpressed in the stroma of most head and neck squamous cell carcinomas (HNSCC) and correlated positively with alpha smooth muscle actin expression (Parajuli et al., 2017) . In addition, ITGA11 was overexpressed by cancer-associated fibroblast (CAFs) in Pancreatic Ductal Adenocarcinoma (PDAC) stroma and may serve as an interesting stromal therapeutic target (Schnittert et al., 2019) . Integrin subunit β4, also known as a laminin-5 receptor, is a protein encoded by ITGB4 (Wang et al., 2012) . Inhibition of ITGB4 in glioma cells would decrease the selfrenewal abilities of glioma stem cells and suppress the malignant behaviors of glioma cells in vitro and in vivo (Ma et al., 2019) . Moreover, higher ITGB4 expression level was detected in tumor than adjacent non-tumor tissues in patients with hepatocellular carcinoma (HCC). Silencing of ITGB4 could repress cell proliferation, colony forming ability and cell invasiveness (Li et al., 2017) . Integrin β8, paired with αv subunit, is encoded by ITGB8. It has been reported that ITGB8 is upregulated in laryngeal squamous cell carcinoma (Ni et al., 2012) . Additionally, the expression level of ITGB8 can be regulated by the tumor-promoting receptor tyrosine kinase-EphB4, while knockdown of ITGB8 may suppress migration and invasion in prostate cancer cell lines (Mertens-Walker et al., 2015) . These studies have shown that ITGA11, ITGB4 and ITGB8 might be candidate biomarkers and therapeutic targets with great potential.
Recent years, there have been developed multifarious platforms, databases as well as various datasets on the web that allow cancer researchers to make in-depth bioinformatic analysis in cancer with multi omics data. Several prognostic biomarkers with great potential for NSCLC have also been identified. For instance, it has been reported that STMN1 expression was correlated with poor OS in patients with Squamous Cell Lung Carcinoma (LUSC) and might serve as a prognostic biomarker (Bao et al., 2017) . Using bioinformatics methods, Xie et al. (2019) have found that KRT8 expression might be an independent prognostic biomarker for poor OS and PFS in Lung Adenocarcinoma (LUAD). Sun et al. (2019) have identified five genes that could predict metastasis in NSCLC and might serve as potential targets. As far as we know, bioinformatics analysis has not been applied to explore the roles of ITGA11, ITGB4 and ITGB8 in NSCLC. Therefore, we conducted this study to analyze the expression patterns and prognostic values of these three genes in NSCLC based on online databases, platforms and various datasets.
MATERIALS AND METHODS

ONCOMINE analysis
The expression levels of ITGA11, ITGB4 and ITGB8 and genes co-expressed with ITGA11, ITGB4 and ITGB8 were analyzed in ONCOMINE database (https://www.oncomine.org) (Rhodes et al., 2007; Rhodes et al., 2004) . The cut-off of p value and fold change were defined as 0.01 and 2, respectively (Huang et al., 2019) .
GEPIA (Gene Expression Profiling Interactive Analysis) analysis
GEPIA (http://gepia.cancer-pku.cn/) is an interactive web application for gene expression analysis based on 9736 tumors and 8587 normal samples from the TCGA (The Cancer Genome Atlas) and the GTEx (Genotype-Tissue Expression) databases (Tang et al., 2017) . The GEPIA database was used to compare mRNA levels of ITGA11, ITGB4 and ITGB8 between TCGA and GTEx databases. Meanwhile, the association among ITGA11, ITGB4 and ITGB8 in NSCLC were also analyzed in GEPIA.
Bioinformatics analysis of data using The Cancer Genome Atlas lung cancer datasets
The level 3 data of TCGA-LUAD and TCGA-LUSC were obtained from UCSC Xena platform (https://xenabrowser.net/datapages/) (Goldman et al., 2015) and RTCGA package (https://rtcga.github.io/RTCGA). The LUAD and LUSC gene expression RNAseq datasets included 524 tumor tissues and 499 tumor tissues, respectively. 502 of the LUAD patients and 492 of the 499 LUSC patients had complete survival data. The differences in overall survival (OS) of LUAD and LUSC patients with high and low expression of ITGA11, ITGB4 and ITGB8 were assessed by Kaplan-Meier curves. Meanwhile, the association between tumor stage and the expression levels of ITGA11, ITGB4 and ITGB8 were also analyzed. Clinicopathological parameters, including age at diagnosis, gender, vital status, tumor stage, smoking history and OS time, were extracted for univariate and multivariate cox regression analysis.
Gene Expression Omnibus (GEO) microarray datasets analysis
To validate the expression profiles of ITGA11, ITGB4 and ITGB8 in NSCLC, we collected a total of 21 datasets including tumor and non-tumor tissues of NSCLC in GEO database (https://www.ncbi.nlm.nih.gov/geo/). We analyzed the mRNA levels of ITGA11, ITGB4 and ITGB8 between tumor and non-tumor controls for each GEO dataset. In addition, we performed a meta-analysis based on the enrolled GEO microarray datasets.
Immunohistochemistry analysis
The protein expression of ITGA11, ITGB4 and ITGB8 in normal lung and tumor tissues were examined using the Human Protein Atlas (HPA) (https://www.proteinatlas.org/) (Uhlen et al., 2015; Uhlen et al., 2017) .
Statistical analysis
Statistical analysis was performed on R software (3.6.1) (https://www.r-project.org/) and an integrated development environment RStudio (1.2.1335) (https://rstudio.com/). The mRNA expression of ITGA11, ITGB4 and ITGB8 between NSCLC tissues and normal controls were compared using Student's t -test. Data visualization was performed using an R package called ''ggstatsplot'' (https://CRAN.R-project.org/package=ggstatsplot). Kaplan-Meier curves of OS were performed in TCGA-LUAD and TCGA-LUSC raw data by setting median expression of ITGA11, ITGB4 and ITGB8 as cut-off. Statistical differences were assessed by the log-rank test. Univariate and multivariate survival analyses were performed using cox regression model, risk factors (p < 0.2) analyzed by univariate analysis were selected for multivariate analysis.
For GEO datasets analysis, mean (M) and standard deviation (SD) were calculated for each NSCLC tumor and normal control group. In addition, an R package called ''meta'' was used in R to perform a comprehensive meta-analysis (Schwarzer, 2007) . The Q test and I 2 statistic were calculated to assess the heterogeneity among the enrolled studies. If p < 0.05 or I 2 >50%, a random effects model would be selected. Sensitivity analysis was conducted to explore whether a specific study played a crucial influence in significant heterogeneity. Finally, the publication bias was examined through funnel plots and Egger's test (Egger et al., 1997) . Once there was a publication bias, the ''fill and trim'' method would be selected to adjust for the bias (Duval & Tweedie, 2000) . p < 0.05 deemed statistically significant.
RESULTS
The expression levels of ITGA11, ITGB4 and ITGB8 in patients with non-small cell lung cancer
Using ONCOMINE database, we investigated the transcription levels of ITGA11, ITGB4 and ITGB8 in lung cancer vs. normal samples. ONCOMINE analysis revealed that the mRNA expression of ITGA11, ITGB4 and ITGB8 were obviously overexpressed in NSCLC tissues in ten datasets (Fig. 1) . These datasets were summarized in Table 1 . The GEPIA analysis results also suggested that the expression levels of ITGA11 and ITGB4 were significantly higher in both LUAD and LUSC than that in normal tissues, while the expression level of ITGB8 was only significantly upregulated in LUSC tissues (Fig. 2 ). Furthermore, we analyzed ITGA11, ITGB4 and ITGB8 mRNA expression level in both lung cancer and normal tissues using the TCGA-LUAD and TCGA-LUSC original data. The results revealed that the expression levels of ITGA11, ITGB4 and ITGB8 were all significantly upregulated in tumor tissues compared with normal tissues (Fig. S1 ).
To further explore the protein expression of ITGA11, ITGB4 and ITGB8 in NSCLC, we analyzed the IHC images using the Human Protein Atlas (HPA) database. As shown in Fig. 3 , the protein expression of ITGA11 and ITGB4 were upregulated in both LUAD and LUSC cancer tissues compared with normal lung tissues (Figs. 3A-3C and 3D-3F). In comparison, the protein expression of ITGB8 was obviously upregulated in LUSC with medium staining, but not in LUAD (Figs. 3G-3I). Confirmation of the expression profiles of ITGA11, ITGB4 and ITGB8 in non-small cell lung cancer using GEO datasets
We also performed a data-mining analysis to investigate the differences in the expression levels of ITGA11, ITGB4 and ITGB8 between tumor and normal tissues in NSCLC using GEO datasets. The main characteristics of the enrolled GEO studies were described in Table S1 . The results were shown in Fig. 4 and Figs. S2-S4. As illustrated in Fig. 4A and Fig. S2D , the expression level of ITGB4 was significantly increased in tissues from patients with LUAD (SMD: 0.94; 95% CI [0.65-1.24]; p < 0.01) as well as LUSC (SMD:1.37; 95% CI [0.71-2.04]; p < 0.01) compared to the normal tissues. The heterogeneity was apparent for LUAD (I 2 = 80%; p < 0.01) and LUSC (I 2 = 89%; p < 0.01). The following sensitivity analysis demonstrated that no study was found to have a vital influence in the enrolled studies ( Fig. 4B and Figs. S3D) . In addition, we didn't find evidence of publication bias based on the funnel plot and the Egger's test (Fig. 4C , p = 0.7759). However, the Figs. S4D indicated publication bias (Egger's test, p = 0.04729). Therefore, we used the fill and trim method to adjust for the bias. The adjusted random effects model result showed that ITGB4 was also significantly upregulated in LUSC tissues (SMD: 0.77; 95% CI [0.03-1.52]; p = 0.04). The analysis results of ITGA11 and ITGB8 mRNA levels in LUAD and LUSC were the same as the above results (Figs. S2-S4 ). The separate analyses of the expression levels of ITGA11, ITGB4 and ITGB8 in LUAD and LUSC tissues compared with normal tissues for each GEO dataset were presented in the Figs. S5 and S6.
The prognostic values of ITGA11, ITGB4 and ITGB8 in non-small cell lung cancer
By using GEPIA, we investigated the prognostic values of ITGA11, ITGB4 and ITGB8 in NSCLC. The survival curves revealed that high expression level of ITGB4 could indicate a poor OS in LUAD (p <0.001; Fig. 5B ), while ITGA11 and ITGB8 were not related with OS in LUAD (p = 0.064 and p = 0.78, respectively, Figs. 5A and 5C ). In comparison, there were no obvious associations between the expression levels of ITAG11, ITGB4 and ITGB8 and LUSC (Figs. 5D-5F ). Moreover, using the TCGA original data, we performed survival analysis to validate these associations. The results were consistent with GEPIA analysis (Fig. S7 ). Next, we performed cox regression analysis to further assess and validate the prognostic values of ITGA11, ITGB4 and ITGB8 in NSCLC based on TCGA original data. The univariate cox analysis indicated that high ITGB4 expression and advanced stages were significantly correlated with worse OS in LUAD (Table 2) . Meanwhile, multivariate cox analysis confirmed that high ITGB4 expression was an independent prognostic biomarker for patients with LUAD (HR: 1.417; 95%CI [1.042-1.926]; p = 0.026; Table 2 ). In addition, no significant results were found with other genes in the OS of LUAD and LUSC (Table 2) . These results were consistent with that analyzed by GEPIA. Furthermore, we investigated the correlation between tumor stage and the expression levels of ITGA11, ITGB4 and ITGB8 (Fig. S8) . The results showed that there was a significant correlation between tumor stage and mRNA expression of ITGB8 in LUSC (Fig. S8F ).
Co-expression and correlation analyses of ITGA11, ITGB4 and ITGB8 in non-small cell lung cancer
The co-expression analysis was conducted using ONCOMINE database. Based on Hou Lung dataset (Hou et al., 2010) , we analyzed genes that were co-expressed with ITGA11, the result showed that ITGA11 was co-expressed with COL10A1, THBS2, SULF1, CTRHC1, GREM1, C5orf46, COL11A1, NOX4 (Fig. S9A) . The Bild Lung dataset indicated that ITGB4 was co-expressed with LAD1, SFN, FXYD3, KRT19, DSG2, JUP, DSP, PERP (Bild et al., 2006) (Fig. S9B ). Based on Yamagata Lung dataset (Yamagata et al., 2003) , we analyzed genes that were co-expressed with ITGB8, the result showed that ITGB8 was co-expressed with ERC2, PDE6D, C17orf99, SNRNP27, C1orf61, GATA1, PPP2R2B, CCK, CRYBA1, APBA3, CYP3A4, UROS (Fig. S9C ). By using GEPIA, we investigated the association among ITGA11, ITGB4 and ITGB8 in NSCLC based on Pearson correlation analysis. The results indicated that there was no correlation between ITGA11 and ITGB4 (R = −0.018; p > 0.05) (Fig. S10A) . Also, there was scarcely any correlation between ITGA11 and ITGB8 (R = 0.069; p < 0.05) (Fig. S10B) . In addition, a weak positive correlation was found between ITGB8 and ITGB4 (R = 0.32; p < 0.05) (Fig. S10C ).
DISCUSSION
Numerous studies have suggested that ITGA11, ITGB4 and ITGB8 are involved in migration, epithelial-mesenchymal transition, invasion, and metastasis in different cancers (Gan et al., 2018; Huang et al., 2017; Kitajiri et al., 2002; Li et al., 2017) . The aberrant expression of ITGA11, ITGB4, and ITGB8 have been reported in many cancers (Grossman et al., 2000; Mertens-Walker et al., 2015; Parajuli et al., 2017; Tagliabue et al., 1998) . Regrettably, the expression profiles and prognostic roles of ITGA11, ITGB4 and ITGB8 in NSCLC are still not clear. Thus, we conducted this study to explore the expression patterns and prognostic values of ITGA11, ITGB4 and ITGB8 in NSCLC.
It has been reported that ITGA11 could serve as an important stromal factor in NSCLC, which can enhance tumorigenicity of human non-small cell lung cancer cells by regulating IGF2 expression in fibroblasts (Zhu et al., 2007) . Moreover, in carcinoma-associated fibroblasts (CAFs), ITGA11 signaling pathway may play an important role in carcinomaassociated fibroblasts (CAFs), which means Integrin α11β1 can promote tumor growth and metastatic potential of NSCLC cells by regulating cancer stromal stiffness (Navab et al., 2016) . These results suggested that ITGA11 might play an important role for NSCLC. In our study, ONCOMINE analysis showed that mRNA expression level of ITGA11 was highly expressed in Lung Adenocarcinoma compared with that in normal controls. GEPIA revealed that the expression level of ITGA11 was obviously higher in both LUAD and LUSC than that in normal tissues. In addition, we also downloaded TCGA original data, GEO datasets, and protein expression data from HPA to validate ITGA11 expression profile, the results were consistent with the GEPIA analysis results. These results indicated that ITGA11 might be a diagnostic biomarker for patients with LUAD and LUSC. Furthermore, we investigated the association between the expression level of ITGA11 and OS in LUAD and LUSC using GEPIA and cox regression analysis. However, the results showed ITGA11 expression had no prognostic role in terms of OS in LUAD and LUSC.
ITGB4 was found to have a strong positive correlation with tumor size (p = 0.01) and tumor nuclear grade (p < 0.01) in early breast cancer (Diaz et al., 2005) . Furthermore, it is reported that ITGB4 could promote the invasion and metastasis of tumor cells through a series of processes (Stewart & O'Connor, 2015) . These results imply us that ITGB4 might also play a crucial role in NSCLC. In our report, ONCOMINE and GEPIA analysis revealed that the expression level of ITGB4 was significantly upregulated in LUAD and LUSC. Additionally, we confirmed this expression feature by analysis TCGA original data and GEO datasets. The protein level was also consistent with the mRNA expression level. Taken together, these results implied that ITGB4 expression could act as a diagnostic biomarker for patients with LUAD and LUSC. Moreover, the survival curve showed that high ITGB4 expression was strong correlated with inferior OS in LUAD. The following univariate cox and multivariate cox regression analysis confirmed that high ITGB4 expression level was an independent prognostic biomarker for poor OS in LUAD.
It has been reported that ITGB8 could mediate the activation of latent TGF-β, which subsequently derives the epithelial-to-mesenchymal (EMT) transition of some cancers and contributes to cancer cell migration and growth (Mu et al., 2002; Pozzi & Zent, 2011) . Furthermore, ITGB8 was significantly upregulated in ovarian cancer tissues compared with that in normal ovary tissues (He et al., 2018) . Moreover, It has been reported that ITGB8 silencing could suppress the metastatic potential of human lung cancer cell lines A549 and PC (Xu & Wu, 2012) . These studies suggested that ITGB8 might play an important role in NSCLC. In our study, we found that the mRNA expression level of ITGB8 was highly overexpressed in LUSC both in ONCOMINE and GEPIA analysis. This expression feature was successfully validated by analyzing the TCGA original data and GEO datasets. These results suggested that ITGB8 might act as a diagnostic biomarker in LUSC. It was worth mentioning that there was no significant correlation in ITGB8 expression level between LUAD and normal tissues by GEPIA analysis. However, the expression feature was not showed when we analyzed the TCGA original data and GEO datasets. This may due to the lack of normal controls in TCGA datasets and the differences in enrolled participants in GEO datasets. Future large-scale studies are required to assess and validate this expression pattern. In addition, we explored the association between the expression level of ITGB8 and OS in LUAD and LUSC using GEPIA and cox regression analysis. the results showed ITGB8 expression had no prognostic role in terms of OS in LUAD and LUSC. Furthermore, we found that there was a strong correlation between ITGB8 expression level and tumor stage in LUSC.
The potential limitations of our study need to be noted. First, the biological mechanisms of these three candidate markers in LUAD and LUSC are still unknown. Second, although this study had a comprehensive analysis based on several databases such as TCGA and GEO, traditional in-house experimental studies including enough specimens are required to further validate our findings.
CONCLUSIONS
In summary, we systematically analyzed the expression patterns and prognostic values of ITGA11, ITGB4 and ITGB8 in patients with LUAD and LUSC by conducting a bioinformatics analysis based on several web platforms and various datasets. Our results indicated that ITGA11 and ITGB4 might act as diagnostic biomarkers for both LUAD and LUSC, while ITGB8 may serve as diagnostic biomarker for LUSC. Furthermore, ITGB4 might serve as a potential prognostic biomarker for LUAD. We hope our findings will enrich the knowledge of diagnostic and therapy designs for patients with NSCLC.
